James Clayton Olson

US Patent:

7025684, Apr 11, 2006

Filed:

May 28, 2003

Appl. No.:

10/447020

Inventors:

John C. Frana - Loves Park IL, US
James N. Olson - Rockford IL, US
Sean M. Carlini - Rockford IL, US

Assignee:

Aircraft Gear Corporation - Rockford IL

International Classification:

F16D 3/224

US Classification:

464145, 464906

Abstract:

A universal joint includes an inner race, an outer race, a ball cage, and balls positioned within windows of the ball cage. One end of the ball cage extends beyond the windows further than the other end of the ball cage.

US Patent:

20070154965, Jul 5, 2007

Filed:

Nov 14, 2006

Appl. No.:

11/600004

Inventors:

Miqin Zhang - Bothell WA, US
James Olson - Seattle WA, US
Raymond Sze - Mercer Island WA, US
Richard Ellenbogen - Seattle WA, US
Omid Veiseh - Kirkland WA, US
Conroy Sun - Kirkland WA, US
Jonathan Gunn - Seattle WA, US

International Classification:

G01N 33/574

US Classification:

435007230, 435455000, 977902000

Abstract:

Chlorotoxin-labeled nanoparticles that target primary brain tumors, compositions that include the nanoparticles, methods of imaging tissues using the nanoparticles, and methods for treating tissues using the nanoparticles.

US Patent:

20080279780, Nov 13, 2008

Filed:

Aug 31, 2007

Appl. No.:

11/897721

Inventors:

Miqin Zhang - Bothell WA, US
Richard G. Ellenbogen - Seattle WA, US
Raymond W. Sze - Mclean VA, US
Omid Veiseh - Kirkland WA, US
James M. Olson - Seattle WA, US
Mandana Veiseh - Emeryville CA, US
Patrick Gabikian - Seattle WA, US

Assignee:

Washington, University of - Seattle WA
Fred Hutchinson Cancer Research Center - Seattle WA

International Classification:

A61K 49/00

US Classification:

424 96

Abstract:

A chlorotoxin conjugate detectable by fluorescence imaging that allows for intra-operative visualization of cancerous tissues, compositions that include the chlorotoxin conjugate, and methods for using the chlorotoxin conjugate.

US Patent:

20130195760, Aug 1, 2013

Filed:

Nov 9, 2012

Appl. No.:

13/673779

Inventors:

Fred Hutchinson Cancer Research Center - Seattle WA, US
James M. Olson - Seattle WA, US

Assignee:

FRED HUTCHINSON CANCER RESEARCH CENTER - Seattle WA

International Classification:

C07K 14/47

US Classification:

424 91, 530324, 514 193, 530322

Abstract:

Chlorotoxin variants, chlorotoxin variant conjugates, compositions that include the chlorotoxin variants or conjugates, and methods for using the chlorotoxin variants, conjugates, and compositions.

US Patent:

57957231, Aug 18, 1998

Filed:

Aug 7, 1997

Appl. No.:

8/910973

Inventors:

Stephen J. Tapscott - Seattle WA
James M. Olson - Seattle WA

Assignee:

Fred Hutchinson Cancer Research Center - Seattle WA

International Classification:

C12Q 168
C12Q 104
C12P 2102
C07H 2104

US Classification:

435 6

Abstract:

Provided are methods of classifying and prognosticating human neuroectodermal tumors by analyzing a sample of the tumor to determine whether various bHLH proteins are detectably expressed in the sample. In the methods disclosed herein, expression of the bHLH genes is assessed by measuring transcripts or proteins expressed from the genes.

US Patent:

20210309755, Oct 7, 2021

Filed:

Apr 6, 2021

Appl. No.:

17/223871

Inventors:

- Seattle WA, US
Ashok BANDARANAYAKE - Lake Stevens WA, US
Christopher MEHLIN - Seattle WA, US
James M. OLSON - Seattle WA, US
Soheil MESHINCHI - Seattle WA, US

International Classification:

C07K 16/30
C07K 16/28
G01N 33/574

Abstract:

Mesothelin (MSLN) is expressed on pancreatic cancers, ovarian cancers and mesotheliomas. The present disclosure provides antigen-binding molecules, including anti-MSLN antibodies, and bispecific antigen-binding molecules that bind to both MSLN and a T cell antigen (e.g., CD3) and activate T cells in the presence of MSLN-expressing tumor cells. The antigen-binding molecules of this disclosure are useful for the treatment of diseases and disorders in which a MSLN-targeted immune response is desired and/or therapeutically beneficial. For example, the antigen-binding molecules of the present disclosure are useful for the treatment of various cancers, including pancreatic cancer, ovarian cancer and mesotheliomas.

US Patent:

20210252159, Aug 19, 2021

Filed:

Apr 19, 2019

Appl. No.:

17/049148

Inventors:

- Seattle WA, US
Julian A. SIMON - Seattle WA, US
Chunfeng YIN - Redmond WA, US
Christopher MEHLIN - Seattle WA, US
Michelle L. COOK SANGAR - Kenmore WA, US
Andrew James MHYRE - Kenmore WA, US
Joseph Michael BEATY - Seattle WA, US
James OLSON - Seattle WA, US

International Classification:

A61K 47/64
A61K 47/54
A61K 31/573
A61K 31/58
A61P 19/02
A61P 37/06

Abstract:

Compositions such as pharmaceutical compositions and uses for peptide-drug conjugates are disclosed. Such compositions can deliver a drug, a peptide, or a conjugate thereof to a target region, tissue, structure or cell in cartilage.

US Patent:

20200330603, Oct 22, 2020

Filed:

Dec 9, 2016

Appl. No.:

16/061179

Inventors:

- Seattle WA, US
James M. Olson - Seattle WA, US
Emily J. Girard - Renton WA, US
Colin E. Correnti - Seattle WA, US
Theo L. Sottero - Seattle WA, US

Assignee:

FRED HUTCHINSON CANCER RESEARCH CENTER - Seattle WA

International Classification:

A61K 47/64
A61K 47/54
A61P 13/12

Abstract:

The present disclosure provides compositions and methods for renal therapy. In various aspects, the present disclosure provides a composition comprising a knotted peptide, wherein upon administration to a subject the knotted peptide homes, targets, is directed to, accumulates in, migrates to, is retained by, and/or binds to renal tissue of the subject. In various aspects, the composition further comprises an active agent coupled to the knotted peptide. The composition, when administered to the subject, may induce protective preconditioning or acquired cytoresistance.